Did Stryker beat expectations and raise guidance?

The filing shows strong sales and earnings growth and an increase in full-year guidance: organic growth is now expected at 9.0% to 10.0%, and adjusted EPS at $11.90 to $12.10. The filing does not include consensus estimates, so a comparison against expectations cannot be made from this document alone.

What is driving growth?

Growth was driven mainly by unit volume, which contributed 7.9 points of the 9.0% organic growth. Pricing added 1.1 points, with MedSurg and Neurotechnology benefiting from pricing (2.1 points) and Orthopaedics and Spine seeing a small price decline (0.4 points). Management cited sustained procedural volumes and healthy demand for capital equipment.

How much of the reported EPS and sales growth is affected by currency and M&A?

Foreign exchange reduced reported sales growth by about 0.9 points in the quarter, while acquisitions added about 0.4 points. Constant-currency growth was 9.4%. Management expects FX to be a moderate headwind to full-year sales and a $0.10 to $0.15 headwind to adjusted EPS if current rates hold.

Is there any cash flow or balance sheet concern?

Cash and equivalents fell to $1.87 billion from $2.97 billion at year-end 2023. Six-month operating cash flow was $837 million, down from $1.13 billion, due to a $1.29 billion working capital and other outflow. Debt was reduced by $600 million, and inventories increased to $5.04 billion. Investors may want to watch whether working capital improves in the second half.

What do the GAAP and adjusted results differ by?

The gap between reported and adjusted EPS ($2.14 vs. $2.81) is mainly due to amortization of purchased intangibles ($0.33 per share), structural optimization and other special charges ($0.15), and tax matters ($0.09). Adjusted measures exclude these items, so investors should weigh both GAAP and non-GAAP results.

SYK 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Stryker (SYK) reported second quarter 2024 results that beat the top-line and earnings trend, with reported net sales up 8.5% to $5.4 billion^a (9.4% in constant currency and 9.0% organic).

Growth was broad-based: MedSurg and Neurotechnology sales rose 9.0% to $3.1 billion^b (9.7% organic), and Orthopaedics and Spine rose 7.9% to $2.3 billion (8.0% organic). Organic growth was driven mainly by unit volume (7.9%), with a modest 1.1% contribution from price. Reported diluted EPS rose 10.9% to $2.14, and adjusted diluted EPS rose 10.6% to $2.81.

Adjusted operating margin expanded 30 bps to 24.6%^c, consistent with management's margin expansion goals. Management raised its full-year 2024 guidance. Organic net sales growth is now expected at 9.0% to 10.0%, with a favorable pricing impact of about 0.5%.

Adjusted diluted EPS guidance is $11.90 to $12.10^d, which reflects an expected $0.10 to $0.15 headwind from foreign exchange if current rates hold. Management cited sustained procedural volumes and healthy demand for capital products as the basis for the outlook. On the balance sheet, cash fell to $1.9 billion from $3.0 billion at year-end 2023, as debt repayments of $600 million and dividends of $609 million outweighed operating cash flow.

Operating cash flow for the first half was $837 million, down from $1.13 billion a year earlier, mainly due to a $1.29 billion working capital and other outflow. Inventories rose to $5.0 billion.

Long-term debt declined to $10.1 billion, and shareholders' equity increased to $19.8 billion. Investors may want to monitor working capital normalization and cash conversion in coming quarters.

02—Key points

Key Highlights

Reported net sales rose 8.5% to $5.4 billion; organic growth was 9.0%, with 7.9 points from unit volume and 1.1 points from price.
MedSurg and Neurotechnology grew 9.0% reported (9.7% organic) to $3.1 billion; Orthopaedics and Spine grew 7.9% reported (8.0% organic) to $2.3 billion.
Adjusted operating income margin expanded 30 bps year over year to 24.6%; reported operating margin was 19.4%.
Adjusted diluted EPS grew 10.6% to $2.81 (reported $2.14, up 10.9%).
Full-year 2024 guidance raised: organic net sales growth of 9.0% to 10.0% and adjusted diluted EPS of $11.90 to $12.10, with a $0.10 to $0.15 FX headwind.
Cash declined to $1.9 billion from $3.0 billion at year-end 2023, and first-half operating cash flow fell to $837 million from $1.13 billion.
U.S. sales grew 9.1% in the quarter, while international sales grew 7.0% reported (10.5% constant currency).

03—Questions

Frequently Asked Questions

Did Stryker beat expectations and raise guidance?
The filing shows strong sales and earnings growth and an increase in full-year guidance: organic growth is now expected at 9.0% to 10.0%, and adjusted EPS at $11.90 to $12.10. The filing does not include consensus estimates, so a comparison against expectations cannot be made from this document alone.
What is driving growth?
Growth was driven mainly by unit volume, which contributed 7.9 points of the 9.0% organic growth. Pricing added 1.1 points, with MedSurg and Neurotechnology benefiting from pricing (2.1 points) and Orthopaedics and Spine seeing a small price decline (0.4 points). Management cited sustained procedural volumes and healthy demand for capital equipment.
How much of the reported EPS and sales growth is affected by currency and M&A?
Foreign exchange reduced reported sales growth by about 0.9 points in the quarter, while acquisitions added about 0.4 points. Constant-currency growth was 9.4%. Management expects FX to be a moderate headwind to full-year sales and a $0.10 to $0.15 headwind to adjusted EPS if current rates hold.
Is there any cash flow or balance sheet concern?
Cash and equivalents fell to $1.87 billion from $2.97 billion at year-end 2023. Six-month operating cash flow was $837 million, down from $1.13 billion, due to a $1.29 billion working capital and other outflow. Debt was reduced by $600 million, and inventories increased to $5.04 billion. Investors may want to watch whether working capital improves in the second half.
What do the GAAP and adjusted results differ by?
The gap between reported and adjusted EPS ($2.14 vs. $2.81) is mainly due to amortization of purchased intangibles ($0.33 per share), structural optimization and other special charges ($0.15), and tax matters ($0.09). Adjusted measures exclude these items, so investors should weigh both GAAP and non-GAAP results.

04—Continue

← View all 8-K filings